Finance Home - My Yahoo - Yahoo! - Help

Sunday, December 6, 2009, 1:54AM ET - U.S. Markets Closed. Dow  0.22% Nasdaq  0.98%

AEterna Zentaris Inc. (AEZS)

On Dec 4: 1.12   0.06 (5.66%)

MORE ON AEZS

Quotes Summary Real-Time Options Historical Prices Charts Interactive Basic Chart Basic Tech. Analysis News & Info Headlines Financial Blogs Company Events Message Board Company Profile Key Statistics SEC Filings Competitors Industry Components Analyst Coverage Analyst Opinion Analyst Estimates Research Reports Star Analysts Ownership Major Holders Insider Transactions Insider Roster Financials Income Statement Balance Sheet Cash Flow

Headlines Get Headlines for:
Change Display [ hide $$  edit ] Wed, Dec 2, 2009 • AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma PR Newswire (Wed, Dec 2) • Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma PR Newswire (Wed, Dec 2) Mon, Nov 30, 2009 • 13 Biotechs to Watch for at Hematology Conference at Seeking Alpha (Mon, Nov 30) Tue, Nov 24, 2009 • Emerging Stock Report Initiates Independent Research Coverage on AEterna Zentaris Inc. GlobeNewswire (Tue, Nov 24) • Tellabs, Zagg: Early Volume Plays at TheStreet.com (Tue, Nov 24) • AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer PR Newswire (Tue, Nov 24) Thu, Nov 12, 2009 • New Star Analyst Rankings for AEterna Zentaris, Inc. StarMine (Thu, Nov 12) Wed, Nov 11, 2009 • AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology PR Newswire (Wed, Nov 11) • Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology PR Newswire (Wed, Nov 11) • Q3 2009 Aeterna Zentaris Inc. Earnings Release - Before Market Open CCBN (Wed, Nov 11) • AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results PR Newswire (Wed, Nov 11) Mon, Nov 9, 2009 • AEterna Zentaris: Scientific Article Supports Perifosine's Development in Kidney Cancer PR Newswire (Mon, Nov 9) Wed, Nov 4, 2009 • AEterna Zentaris to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009 PR Newswire (Wed, Nov 4) Mon, Nov 2, 2009 • Kopin, Cardionet: Early Volume Plays at TheStreet.com (Mon, Nov 2) • AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer PR Newswire (Mon, Nov 2) Fri, Oct 23, 2009 • AEterna Zentaris Receives US$5.5 Million from Institutional Investors PR Newswire (Fri, Oct 23) Mon, Oct 19, 2009 • AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share PR Newswire (Mon, Oct 19) • AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency PR Newswire (Mon, Oct 19) Thu, Oct 1, 2009 • AEterna Zentaris to Present at BioContact in Quebec City on October 8 PR Newswire (Thu, Oct 1) Wed, Sep 30, 2009 • AEterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary Endpoint PR Newswire (Wed, Sep 30) Older Headlines - Download Recent Headlines View headlines from: Wed, Sep 30, 2009Wed, Sep 23, 2009Wed, Sep 16, 2009Wed, Sep 9, 2009Wed, Sep 2, 2009Wed, Aug 26, 2009Wed, Aug 19, 2009Wed, Aug 12, 2009Wed, Aug 5, 2009Wed, Jul 29, 2009 Add AEZS News to My Yahoo!:
Add to Portfolio     Set Alert     Email to a Friend Get Headlines for Another Symbol: Symbol Lookup • Stocks In Play • Story Stocks • Full Coverage